Lilly's Trulicity label update allows use with basal insulin

9 February 2017

An update to its label means US pharma major Eli Lilly’s (NYSE: LLY) diabetes drug Trulicity (dulaglutide) is the first and only glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in combination with mealtime insulin or basal insulin.

Trulicity was first approved in September 2014 as a once-weekly injectable prescription medicine to improve blood sugar in adults with type 2 diabetes and the US Food and Drug Administration (FDA) has updated the label to include use of the drug in combination with basal insulin.

Sherry Martin, head of global medical affairs at Lilly Diabetes, said: “Despite best efforts to manage their A1C, many adults with type 2 diabetes may need to add to or change their treatment plan to help them reach their blood sugar goals.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK